Treatment patterns and blood count control in 10,112 patients with polycythemia vera
This real-world evidence highlights the importance of considering alternative therapies for patients whose initial treatment regimen does not provide adequate clinical benefit.
Authors
- Evan M. Braunstein (ORCID: https://orcid.org/0000-0001-5072-7636)
- Aleksander L. Chojecki (ORCID: https://orcid.org/0000-0003-2841-8321)
- Jingbo Yu (ORCID: https://orcid.org/0000-0001-9819-0735)
- Naveen Pemmaraju (ORCID: https://orcid.org/0000-0002-1670-6513)
- Anupama Vasudevan (ORCID: https://orcid.org/0000-0002-5750-9479)
- H Qureshi
Institutions
- The University of Texas MD Anderson Cancer Center (US)
- Integra (United States) (US)
- Levine Cancer Institute (US)
- Wake Forest University (US)
- Incyte (United States) (US)
Publication Details
- Journal
- Expert Review of Hematology
- Published
- 2025-06-13
- DOI
- https://doi.org/10.1080/17474086.2025.2520316
- Primary Topic
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Incyte